

Figure 2. Expression of Allergin-1 isoforms on CB-MC and PB-MC. A. Structure of human and mouse Allergin-1. Unlike mouse Allergin-1, human Allergin-1 consists of three splice isoforms, Allergin-1L, Allergin-1S1, and Allergin-1S2. The first and second immunoglobulin-like domains in the extracellular portion of Allergin-1L is identical to that of Allergin-1S1 and Allergin-1S2, respectively. B. BW5147 transfectants stably expressing each isoform of Allergin-1 were stained with isotype control, anti-Allergin-1S1-specific EX32, and/or anti-Allergin-1S2-specific EX29 mAbs and were analyzed by using flow cytometry. C. CB-MC and PB-MC were stained with isotype control Abs or with EX32 and EX29 mAbs and were analyzed by using flow cytometry. doi:10.1371/journal.pone.0076160.g002

characterize the human primary MC in the BALF. We obtained the BALF cells from patients with pulmonary diseases and simultaneously stained the cells with PI and mAbs against CD45; the lineage markers CD3, CD19, CD56, CD11b, and CD11c; c-Kit; and FcεRIα and were analyzed by using multicolor flow cytometry. MC were defined as PI⁺CD45⁺Lin⁻c-Kit⁺FcεRIα⁺ cells (Fig. 3A), which comprised 0.153% ± 0.041% (*n* = 28) of the total cell population in BALF. No significant differences were observed in the frequency of MC in BALF (BAL-MC) from patients with pulmonary diseases such as idiopathic interstitial pneumonia, sarcoidosis, or eosinophilic pneumonia (Table S1). Staining of BAL-MC sorted from BALF with Toluidine-blue showed a characteristics of MC with rich granules in the cytoplasm (Fig. 3B).

Expression of Allergin-1 isoforms on human primary MC in BALF

We then conducted a seven-color flow cytometric analysis in which the cells obtained from the BALF of patients with various pulmonary diseases were simultaneously stained with EX32 and EX29, in addition to PI and mAbs against CD45, lineage markers,

c-Kit, and FcεRIα (Fig. 4A). We found diverse expression profiles on BAL-MC among the patients (Fig. 4B), and, in accordance with the results from PB-MC and CB-MC, Allergin-1S1 was dominantly expressed on BAL-MC, compared with Allergin-1L1 or Allergin-1S2 (Fig. 4C).

Expression of Allergin-1 isoforms on human primary MC in the nasal cavity

We also examined MC obtained from the nasal cavity (N-MC) of healthy donors and patients with non-seasonal allergic rhinitis by using multicolor flow cytometry. We detected few N-MC in nasal scratching specimens from healthy donors. In contrast, we clearly observed N-MC in nasal scratching specimens from patients with non-seasonal rhinitis (Fig. 5A). The number of N-MC obtained from rhinitis patients was significantly higher than that from healthy donors (Fig. 5B). Flow cytometric analysis showed that N-MC preferentially expressed Allergin-1S1, rather than Allergin-1L or Allergin-1S2 (Fig. 5C, D), suggesting that Allergin-1S1 is the dominant isoform of Allergin-1 in human primary MC.




Figure 3. Flow cytometric analyses of BAL-MC. A. BALF cells were simultaneously stained with PI, anti-CD45, a mAb cocktail against lineage markers containing anti-CD3, anti-CD19, anti-CD56, anti-CD11b, and anti-CD11c mAbs, anti-CD117 (c-Kit), and anti-FcεRIα and were analyzed by flow cytometry. B. Bronchoalveolar fluid MC (BAL-MC) sorted by flow cytometry were cytopspinned onto glass slides, stained with Toluidine-blue and analyzed by microscopy ($\times 100$).
doi:10.1371/journal.pone.0076160.g003

Allergin-1 inhibits IgE-mediated activation of human cultured and primary MC

We previously demonstrated that colligation of FcεRIα and Allergin-1 inhibits IgE-mediated activation, as determined by β -hexosaminidase release assay, from an RBL-2H3 transfectant expressing mouse Allergin-1 [14]. However, it remained undetermined whether Allergin-1 also inhibits IgE-mediated activation of human primary MC. Because too small number of human primary MC can be obtained to conduct the ELISA assay for chemical mediators such as histamine or β -hexosaminidase released from MC in of BALF samples, we performed an activation assay by utilizing a multicolor flow cytometry. We first established an activation assay for CB-MC and PB-MC and examined whether Allergin-1 inhibits activation by flow cytometry. CB-MC or PB-MC were incubated with TNP-specific mouse IgE and then the TNP-conjugated F(ab')₂ fragment of control Ig or EX33 (anti-Allergin-1L/S1) (Fig. 6A). By using cell surface CD107a as a marker of murine and human mast cell

degranulation [17–19], we detected CB-MC and PB-MC that turned to be positive for CD107a expression on the cell surface when the MC were stimulated with anti-TNP IgE followed by TNP-conjugated control mAb (Fig. 6B). However, CD107a⁺ cells were significantly decreased when FcεRIα was colligated with Allergin-1 with anti-TNP IgE and TNP-conjugated anti-Allergin-1 mAb (Fig. 6B, C). Since CB-MC and PB-MC preferentially express Allergin-1S1, but neither Allergin-1L nor Allergin-1S2, these results indicated that Allergin-1S1 inhibits IgE-mediated activation from cultured human MC.

We then examined the inhibitory function of Allergin-1 on MC in BALF. BALF cells were also stimulated and then stained with anti-CD107a and mAbs for the identification of BAL-MC, as described above, and analyzed by using multi-color flow cytometry. We detected a subpopulation of BAL-MC that was positive for CD107a when the BALF cells were stimulated with anti-TNP IgE followed by TNP-conjugated control mAb (Fig. 6D). However, the population of CD107a⁺ MC were




Figure 4. Expression of Allergin-1 isoforms on human BAL-MC. Cells obtained from the BALF of patients with pulmonary diseases were stained with PI, anti-CD45, lineage mAb cocktail, anti-FcεRIα, and anti-c-Kit mAbs together with isotype control, and EX32 and/or EX29 mAb, and the BAL-MC were analyzed by using flow cytometry (A). Representative flow cytometry profiles of five patients are shown (B). “Combinations” indicates MC in the upper right quadrant that express either L+S1, L+S2, L+S1+S2, or S1+S2 (C).
doi:10.1371/journal.pone.0076160.g004




Figure 5. Expression of Allergin-1 isoforms on human N-MC. A, B. NSS cells obtained from 9 patients with allergic rhinitis or 5 healthy donors (non-rhinitis) were stained with PI, anti-CD45, lineage cocktail, anti-FcεRIα, and anti-c-Kit mAbs and analyzed by flow cytometry (A). The frequencies of N-MC population were compared between two groups (B). C, D. NSS cells obtained from 6 patients with allergic rhinitis were stained with mAbs, as described in A, together with EX32 and EX29 mAbs, and analyzed by flow cytometry. Representative flow cytometry profiles of four patients are shown (C). “Combinations” indicates MC in the upper right quadrant that express either L+S1, L+S2, L+S1+S2, or S1+S2 (D). doi:10.1371/journal.pone.0076160.g005

significantly decreased when BAL-MC were stimulated via anti-TNP IgE and TNP-conjugated anti-Allergin-1 mAb (Fig. 6E). Since BAL-MC also preferentially express Allergin-1S1 rather than Allergin-1L or Allergin-1S2, these results indicated that Allergin-1S1 inhibits the IgE-mediated activation of BAL-MC.

Discussion

Previous reports have shown the phenotypical characteristics of human primary MC in bone marrow, lung, skin, intestine, uterus, heart, and ascites by using flow cytometry, in which MC were defined as CD45⁺c-Kit⁺IgE⁺ cells or CD45⁺c-Kit⁺ cells [20,21]. However, c-Kit is also expressed on hematopoietic progenitors, and recent reports further demonstrate that c-Kit is also expressed on natural helper cells [22,23]. MC are distinguished from hematopoietic progenitors and natural helper cells by the expression of FcεRI; however, FcεRIα is also expressed on basophils. In addition, FcεRIα is a component of the FcεRIα trimer expressed on some myeloid lineage cells. Thus, we expected that the co-expression of c-Kit and FcεRIα is not enough for the definition of MC. In this study, we defined human primary MC as PI⁺CD45⁺c-Kit⁺FcεRIα⁺ cells in the Lin⁻ cell population. Indeed, we found that PI⁺CD45⁺c-Kit⁺FcεRIα⁺ cells including the Lin⁺ cells contained a significant population of non-MC contamination (data not shown), thus leading to inaccurate analyses of primary MC.

Previous studies often used conventional histamine, cytokine or β-hexosaminidase release assay by ELISA to investigate activation

of purified and enriched MC obtained from the lung or skin in the presence of growth factors and cytokines [19,24,25]. However, ELISA can hardly be applied for a small amount of protein produced by a very small number of primary uncultured MC. Our approach can be applied to the functional study of human primary MC, even at the extremely low frequencies seen in BALF. The methodology in this study enable us to show the function of inhibitory receptors on human primary MC for the first time.

By using this method together with the simultaneous application of EX32 and EX29, which are mAbs specific to Allergin-1S1 and Allergin-1S2, respectively, we developed a unique approach to analyzing the expression profile of Allergin-1 isoforms on primary MC in BALF and NSS. We demonstrated that Allergin-1S1 was predominantly expressed on MC in both BALF and NSS. A database search identified mouse and rat Allergin-1 that contained a single Ig-like domain in the extracellular portion with amino acid identities of 50% and 52%, respectively, with that of human Allergin-1S1 [14], suggesting that Allergin-1S1 is well conserved. We previously reported that Allergin-1 expression on MC suppresses the development of IgE- and MC-dependent systemic and cutaneous anaphylaxis in mice [14], suggesting that human Allergin-1S1 may also play an important role in allergic responses. In fact, we demonstrated that the Allergin-1S1-mediated signal suppressed FcεRI-mediated activation in primary MC. However, since Allergin-1 is also expressed on myeloid cells, including monocytes, granulocytes and dendritic cells [14], as well as MC in human, a therapeutic approach for allergic diseases by targeting




Figure 6. Allergin-1 inhibits IgE-mediated activation of cultured and primary MC. A-C. CB-MC or PB-MC were left unstimulated or stimulated with anti-TNP IgE together with either TNP-conjugated F(ab')₂ anti-Allergin-1 (specific to Allergin-151) or control Ig, as described in the Methods, and analyzed for the expression of CD107a. D, E. BALF cells were left unstimulated or stimulated, as described in A, and stained with mAbs indicated, as described in the Methods, for MC gating. $p < 0.05$; *, $p < 0.01$; **, $p < 0.001$; ***, $p < 0.0001$. doi:10.1371/journal.pone.0076160.g006

Allergin-1 may be complex. To develop a novel molecular target therapy by using Allergin-1, the role of Allergin-1 on myeloid cells as well as MC in allergic and non-allergic diseases should be clarified.

In this study, we analyzed the MC in BALF from 28 patients with various pulmonary diseases. We observed no significant differences in the frequency of MC among the patients. Previous reports demonstrated that the frequencies of MC, as determined by microscopic analysis, are much higher in BALF from patients with hypersensitivity pneumonitis [26,27], cryptogenic organizing pneumonia [27], extrinsic allergic alveolitis [28], interstitial pneumonia [29,30], or allergic rhinitis and asthma [31] than in healthy controls. We could not compare BAL-MC frequency between patients and healthy controls; however, the frequency of MC in NSS was significantly higher in patients with rhinitis than that in healthy controls, suggesting that recruitment of MC to the nasal mucosa or MC growth within the tissues of the body are augmented in patients with rhinitis.

References

- Galli SJ, Tsai M (2010) Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. *Eur J Immunol* 40: 1843–1851.
- Galli SJ (2000) Mast cells and basophils. *Curr Opin Hematol* 7: 32–39.
- Schwartz LB (1994) Mast cells: function and contents. *Curr Opin Immunol* 6: 91–97.
- Kawakami T, Galli SJ (2002) Regulation of mast-cell and basophil function and survival by IgE. *Nat Rev Immunol* 2: 773–786.
- Sandig H, Bulfone-Paus S (2012) TLR signaling in mast cells: common and unique features. *Front Immunol* 3: 185.
- Galli SJ, Nakae S, Tsai M (2005) Mast cells in the development of adaptive immune responses. *Nat Immunol* 6: 135–142.
- Bischoff SC (2007) Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. *Nat Rev Immunol* 7: 93–104.
- Malbec O, Fong DC, Turner M, Tybulewicz VL, Cambier JC, et al. (1998) Fc epsilon receptor 1-associated tyrosine-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. *J Immunol* 160: 1647–1658.
- Lienard H, Bruhns P, Malbec O, Fridman WH, Daeron M (1999) Signal regulatory proteins negatively regulate immunoreceptor-dependent cell activation. *J Biol Chem* 274: 32493–32499.
- Yotsumoto K, Okoshi Y, Shibuya K, Yamazaki S, Tahara-Hanaoka S, et al. (2003) Paired activating and inhibitory immunoglobulin-like receptors, MAIR-I and MAIR-II, regulate mast cell and macrophage activation. *J Exp Med* 198: 223–233.
- Kumagai H, Oki T, Tamitsu K, Feng SZ, Ono M, et al. (2003) Identification and characterization of a new pair of immunoglobulin-like receptors LMIR1 and 2 derived from murine bone marrow-derived mast cells. *Biochem Biophys Res Commun* 307: 719–729.
- Bachelet I, Munitz A, Moretta A, Moretta L, Levi-Schaffer F (2005) The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. *J Immunol* 175: 7989–7995.
- Masuda A, Nakamura A, Maeda T, Sakamoto Y, Takai T (2007) Cis binding between inhibitory receptors and MHC class I can regulate mast cell activation. *J Exp Med* 204: 907–920.
- Hitomi K, Tahara-Hanaoka S, Someya S, Fujiki A, Tada H, et al. (2010) An immunoglobulin-like receptor, Allergin-1, inhibits immunoglobulin E-mediated immediate hypersensitivity reactions. *Nat Immunol* 11: 601–607.
- Nakahashi-Oda C, Tahara-Hanaoka S, Honda S, Shibuya K, Shibuya A (2012) Identification of phosphatidylserine as a ligand for the CD300a immunoreceptor. *Biochem Biophys Res Commun* 417: 646–650.
- Saito H, Kato A, Matsumoto K, Okayama Y (2006) Culture of human mast cells from peripheral blood progenitors. *Nat Protoc* 1: 2178–2183.
- Gekara NO, Weiss S (2008) Mast cells initiate early anti-Listeria host defences. *Cell Microbiol* 10: 225–236.
- Cheng LE, Hartmann K, Roers A, Krummel MF, Locksley RM (2013) Perivascular mast cells dynamically probe cutaneous blood vessels to capture immunoglobulin E. *Immunity* 38: 166–175.
- Grutzkau A, Smorodchenko A, Lippert U, Kirchoff L, Artuc M, et al. (2004) LAMP-1 and LAMP-2, but not LAMP-3, are reliable markers for activation-induced secretion of human mast cells. *Cytometry A* 61: 62–68.
- Valent P, Scherthaner GH, Sperr WR, Fritsch G, Agis H, et al. (2001) Variable expression of activation-linked surface antigens on human mast cells in health and disease. *Immunol Rev* 179: 74–81.
- Florian S, Sonneck K, Czerny M, Hennersdorf F, Hauswirth AW, et al. (2006) Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies. *Allergy* 61: 1054–1062.
- Hauswirth AW, Florian S, Scherthaner GH, Krauth MT, Sonneck K, et al. (2006) Expression of cell surface antigens on mast cells: mast cell phenotyping. *Methods Mol Biol* 315: 77–90.
- Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, et al. (2010) Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. *Nature* 463: 540–544.
- Oskeritzian CA, Price MM, Hait NC, Kapitonov D, Falanga YT, et al. (2010) Essential roles of sphingosine-1-phosphate receptor 2 in human mast cell activation, anaphylaxis, and pulmonary edema. *J Exp Med* 207: 465–474.
- Zhao W, Oskeritzian CA, Pozez AL, Schwartz LB (2005) Cytokine production by skin-derived mast cells: endogenous proteases are responsible for degradation of cytokines. *J Immunol* 175: 2635–2642.
- Soler P, Nioche S, Valeyre D, Basset F, Benveniste J, et al. (1987) Role of mast cells in the pathogenesis of hypersensitivity pneumonitis. *Thorax* 42: 565–572.
- Schildge J, Klar B, Hardung-Backes M (2003) [Mast cells in bronchoalveolar lavage fluid of patients with interstitial lung diseases]. *Pneumologie* 57: 202–207.
- Haslam PL, Dewar A, Butchers P, Primett ZS, Newman-Taylor A, et al. (1987) Mast cells, atypical lymphocytes, and neutrophils in bronchoalveolar lavage in extrinsic allergic alveolitis. Comparison with other interstitial lung diseases. *Am Rev Respir Dis* 135: 35–47.
- Chlap Z, Jedynak U, Sladek K (1998) [Mast cell: its significance in bronchoalveolar lavage fluid cytologic diagnosis of bronchial asthma and interstitial lung disease]. *Pneumonol Alergol Pol* 66: 321–329.
- Hunt LW, Colby TV, Weiler DA, Sur S, Butterfield JH (1992) Immunofluorescent staining for mast cells in idiopathic pulmonary fibrosis: quantification and evidence for extracellular release of mast cell tryptase. *Mayo Clin Proc* 67: 941–948.
- Casale TB, Wood D, Richerson HB, Trapp S, Metzger WJ, et al. (1987) Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness. *J Clin Invest* 79: 1197–1203.

Supporting Information

Table S1 The patients' background. IIP; idiopathic interstitial pneumonia, CVD-ILD; collagen vascular disease associated interstitial lung disease, BALF; bronchoalveolar lavage fluid, NSS; nasal scratching specimen, *P = 0.0032 compared to control. (PPTX)

Table S2 Profile of antibodies used in this study. (PPTX)

Acknowledgments

We thank Satoko Mitsubishi for her secretarial assistance.

Author Contributions

Conceived and designed the experiments: KN AS KY ST-H. Performed the experiments: KN. Analyzed the data: KN ST-H KK AS. Contributed reagents/materials/analysis tools: YM TT YI EN SS MI NH SF. Wrote the paper: KN AS.

Cystatin SN Upregulation in Patients with Seasonal Allergic Rhinitis

Yoshimasa Imoto^{1,2}, Takahiro Tokunaga^{1,2}, Yuri Matsumoto², Yuko Hamada², Mizuho Ono², Takechiyo Yamada¹, Yumi Ito¹, Tadao Arinami², Mitsuhiro Okano³, Emiko Noguchi^{2,4*}, Shigeharu Fujieda¹

1 Departments of Otorhinolaryngology Head & Neck Surgery, Faculty of Medical Sciences, University of Fukui, Fukui, Japan, **2** Department of Medical Genetics, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, **3** Departments of Otorhinolaryngology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, University of Okayama, Okayama, Japan, **4** Japan Science and Technology Agency, Core Research for Evolutional Science and Technology (CREST), Tokyo, Japan

Abstract

Seasonal allergic rhinitis (SAR) to the Japanese cedar, *Cryptomeria japonica* (JC) pollen is an IgE-mediated type I allergy affecting nasal mucosa. However, the molecular events underlying its development remain unclear. We sought to identify SAR-associated altered gene expression in nasal epithelial cells during natural exposure to JC pollen. We recruited study participants in 2009 and 2010 and collected nasal epithelial cells between February and April, which is the period of natural pollen dispersion. Fifteen patients with SAR-JC and 13 control subjects were enrolled in 2009, and 17 SAR-JC patients, 13 sensitized asymptomatic subjects (Sensitized), and 15 control subjects were enrolled in 2010. Total RNA was extracted from nasal epithelial cells and 8 SAR-JC patients and 6 control subjects in 2009 were subjected to microarray analysis with the Illumina HumanRef-8 Expression BeadChip platform. Allergen-stimulated histamine release was examined in the peripheral blood basophils isolated from patients with SAR. We identified 32 genes with significantly altered expression during allergen exposure. One of these, *CST1* encodes the cysteine protease inhibitor, cystatin SN. *CST1* expression in nasal epithelial cells was significantly upregulated in both the 2009 and 2010 SAR-JC groups compared with the control groups. Immunohistochemical staining confirmed the increased expression of *CST1* in the nasal epithelial cells of SAR patients. Addition of exogenous *CST1* to basophils inhibited JC allergen-stimulated histamine release in vitro. We propose that *CST1* may contribute to inactivation of protease allergens and help re-establish homeostasis of the nasal membranes.

Citation: Imoto Y, Tokunaga T, Matsumoto Y, Hamada Y, Ono M, et al. (2013) Cystatin SN Upregulation in Patients with Seasonal Allergic Rhinitis. PLoS ONE 8(8): e67057. doi:10.1371/journal.pone.0067057

Editor: Susanne Krauss-Etschmann, Ludwig-Maximilians-University Munich, Germany

Received: January 19, 2013; **Accepted:** May 13, 2013; **Published:** August 12, 2013

Copyright: © 2013 Imoto et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by research grants from Grant-in-Aid for Scientific Research (C) grant number 20590327, from Japan Science and Technology Agency, Japan, and from a Grant-in-Aid for Science Research from the Ministry of Health and Welfare (H23-Immunology-006). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: enoguchi@md.tsukuba.ac.jp

Introduction

Allergic diseases such as asthma and allergic rhinitis are major causes of morbidity in developed countries, and are increasing in frequency. In Japan, the prevalence of rhinitis was 16% in 1992 and 21% in 2002 [1]. Seasonal allergic rhinitis (SAR) due to the Japanese cedar (JC) *Cryptomeria japonica* pollen is an IgE-mediated type I allergy that affects the nasal mucosa and causes sneezing, itchiness, and nasal obstruction. It is one of the most common causes of allergy in Japan and is thus a major public health issue [2]. We have recently reported that the prevalence of allergic rhinitis in Japanese adults is 44.2%, and the most common allergen is the JC pollen [3]. Although all patients with SAR are positive for allergen-specific IgE, it is well known that the presence of specific IgE alone is insufficient to develop SAR. Therefore, there is a gap in our understanding of the events that link sensitization to the development of the disease. Two different basic theories on the pathogenesis of allergy have been suggested. One is that allergy is caused by unbalanced and overactive immunological responses against allergens, mostly driven by infiltration of type 2 helper T lymphocytes (Th2), mast cells, and eosinophils into

the site of allergic diseases. The other more recent hypothesis is dysregulation of the epithelial barrier, so called “epithelial barrier dysfunction hypothesis,” that is, dysfunction and disruption of the epithelial barrier has been suggested for the primary defects in allergic diseases. Disruption of the skin barrier by filaggrin null mutations has been extensively reported to be associated with the development of atopic dermatitis and other allergic diseases [4,5]. Recently, Chen et al. reported that Pen c 13, a major allergen secreted by *Penicillium citrinum*, degraded occludin, zonula occludens (ZO)-1, and E-cadherin by nasal Pen c 13 challenge in BALB/c mice, showing increased airway hyperresponsiveness, inflammatory cell infiltration, and mucous overproduction in the lung, as well as increased total IgE and Pen c 13-specific IgE [6]. These data support the notion that dysfunction of epithelial barriers may lead to allergic diseases.

There have been few investigations at the molecular level of the characteristics that distinguish SAR patients from subjects who are allergen-specific IgE-positive, but remain asymptomatic. Such investigations will be essential to identify the molecular and cellular mechanisms by which allergic diseases develop, and they could lead to the discovery of novel preventive therapeutics.

One approach to understanding the molecular basis of allergic inflammation is to identify the differences in the gene expression during natural allergen exposure of patients with varying disease status. Microarray gene expression profiling permits thousands of genes to be analyzed simultaneously. Recently, we used microarray analysis to show the upregulation of interleukin-17 receptor B (*IL17RB*) expression in CD4⁺ T cells of SAR patients during natural allergen exposure [7]. Our study identified fewer genes that were modulated by allergen than those that had been observed in other microarray studies in which CD4⁺ cells were stimulated in vitro, suggesting that changes in the gene expression during natural exposure to allergen in vivo may be subtle. However, it may be more informative to investigate SAR-related gene expression in nasal mucosa rather than in peripheral blood cells, because nasal mucosa is the site of the allergic inflammatory response. Indeed, a microarray analysis of nasal epithelial samples from patients with allergic patients revealed gene expression signatures that were strongly associated with exacerbated or uncontrolled asthma [8,9]. A recent study using nasal epithelial cells revealed a Th2-driven epithelial phenotype in pediatric patients with house dust mite allergy [8]. Although the entire nasal mucosa and underlying tissues are involved in the development of SAR, we may gain valuable insight into the molecular mechanisms of allergen sensitization and SAR development by comparing gene expression profiles in nasal epithelial cells from healthy subjects, patients with SAR, and sensitized subjects who are positive for allergen-specific IgE, but have not yet developed SAR.

In the present study, we performed a microarray analysis of nasal epithelial cells from SAR patients and Control subjects, and analyzed a candidate gene for RT-PCR using samples of Controls, SAR patients, as well as Sensitized subjects to identify gene signatures that reflect the status of the SAR patient during natural allergen exposure. We observed that the expression of the cysteine protease inhibitor cystatin SN (*CST1*) was upregulated specifically in SAR-JC patients during natural allergen exposure. Our results also showed *CST1* may inhibit JC allergen-stimulated histamine release in vitro.

Methods

Ethics Statement

All participants provided written informed consent, and the study was approved by the ethics committees of the University of Tsukuba and the University of Fukui, Japan.

Subjects

Study participants were selected from 1575 hospital workers and university students, who participated in an epidemiological survey on allergic rhinitis between 2003 and 2007. All participants were of Japanese origin and were residents of Fukui prefecture, Japan. The characteristics of the study population have been described in detail elsewhere [3]. Total and allergen-specific IgE (specific for JC, *Dermatophagoides* [dust mites], *Dactylis glomerata* [orchard grass], *Ambrosia artemisiifolia* [ragweed], or the fungal allergens *Candida albicans* and *Aspergillus* spp.) were measured by the ImmunoCAP method (Pharmacia Diagnostics AB, Uppsala, Sweden).

We invited 14 of the 1575 survey subjects to participate in the microarray analysis study. Samples of nasal epithelial mucosa were collected by brushing the inferior turbinate, between February and April 2009—the period of natural exposure to JC pollen. Eight subjects had SAR due to JC pollen (SAR-JC group), which was diagnosed on the basis of a positive history of rhinitis between February and April and high levels of JC-specific serum IgE.

None of the SAR patients had detectable IgE specific for *Dermatophagoides* spp., *Dactylisglomerata*, *A. artemisiifolia*, *C. albicans*, or *Aspergillus* spp. and none of the subjects had been treated by oral corticosteroid during pollen season when we collected the samples. They had also not taken intranasal and oral corticosteroids for at least 10 months before the collection of samples. All patients were classified as moderate to severe, according to the allergic rhinitis severity (ARIA) classification [10]. The Control group consisted of 6 subjects for whom the inclusion criteria were as follows: (1) no symptoms or history of allergic diseases, (2) no detectable IgE antibodies specific for the 6 common inhalant allergens, the same as the allergens mentioned above, and (3) total serum IgE levels below the general population mean. We also recruited an additional 7 SAR-JC patients and 7 Controls for real-time RT-PCR analysis.

In 2010, we enrolled an additional samples of 17 SAR-JC patients, 13 asymptomatic subjects with JC-specific IgE (Sensitized group), and 15 Control subjects into the study for RT-PCR validation of the microarray data. Subjects in the Sensitized group and SAR-JC group were negative for IgE specific for *Dermatophagoides* spp., *Dactylisglomerata*, *A. artemisiifolia*, *C. albicans*, or *Aspergillus* spp. The characteristics of the subjects are listed in Table 1.

Microarray analysis

Nasal epithelial cells were collected from the 14 subjects in the 2009 by brushing the inferior turbinate with a Cytosoft Cytology Brush (Medical Packaging Co, Camarillo, CA, USA). RNA was extracted using the RNeasy Mini Kit (Qiagen K.K., Tokyo, Japan) according to the manufacturer's instructions. We assessed the quality of total RNA by performing agarose gel electrophoresis and used RNA showing 2 distinct ribosomal peaks corresponding to either 18S or 28S (28S>18S) for microarray and qRT-PCR experiments. Two samples (1 from a SAR patient and 1 from a Control subject) were excluded from the analysis because of the low quality of RNA. Therefore, a total of 12 samples were used for the subsequent microarray analysis.

Microarray assays were performed using the Illumina BeadArray single-color platform (Illumina, San Diego, CA). For the assay, cRNA was synthesized with an Illumina TotalPrep RNA Amplification Kit (Ambion, Austin, TX) according to the manufacturer's instructions. In brief, aliquots of 500 ng of total RNA were reverse transcribed to first- and second-strand cDNA, which was purified by using spin columns, and then transcribed in vitro to yield biotin-labeled cRNA. A total of 750 ng biotin-labeled cRNA was hybridized to each Illumina HumanRef-8 BeadChip array (Illumina) at 55°C for 18 h. The hybridized BeadChip was washed and labeled with streptavidin-Cy3 (GE Healthcare, Waukesha, WI) and then scanned with the Illumina BeadStation 500 System (Illumina). The scanned image was analyzed by using the BeadStudio software (Illumina). In this system, 22,000 transcripts representing 8 whole-genome samples can be analyzed on a single BeadChip. We included at least 1 technical replicate (i.e., the same cRNA sample) for each BeadChip. We used cRNA from the same sample as our technical replicates to determine whether the experiment was performed properly. The correlation coefficients for replicate RNAs were 0.995–0.996 (r^2). Microarray data was deposited in the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo) under references GSE43523.

Quantitative real-time RT-PCR (qRT-PCR)

RNA was isolated from nasal epithelial cells obtained from the 45 subjects in 2010, as described above. We performed qRT-PCR on RNA by using the TaqMan Universal Master Mix and an Assays-on-Demand Gene Expression Kit (Applied Biosystems,

Table 1. Characteristics of subjects for expression analysis.

	SAR-JC	Sensitized	Control	P value
year	2009			
Number of subjects	15	N.A	13	
Male/Female	6/9	N.A	8/5	0.45
Age (mean \pm SD)	37.93 \pm 9.32	N.A	32.85 \pm 7.83	0.13
Total IgE (mean, 95%CI)	44.47 (23.79–83.12)	N.A	36.85 (20.04–67.77)	0.65
Specific IgE (JC) (mean, 95%CI)	8.56 (4.13–17.71)	N.A	<0.34	<0.0001
year	2010			
Number of subjects	17	13	15	
Male/Female	8/9	4/9	6/9	0.64
Age (mean \pm SD)	30.47 \pm 7.83	24.9 \pm 5.75	24.6 \pm 5.46	0.24
Total IgE (mean, 95%CI)	76.52 (53.30–109.84)	61.26 (42.54–88.21)	26.00 (12.06–56.07)	0.0084
Specific IgE (JC) (mean, 95%CI)	16.19 (8.26–31.76)	2.97 (1.37–6.43)	<0.34	<0.0001

N.A, not applicable.

doi:10.1371/journal.pone.0067057.t001

Foster City, CA) according to the manufacturer's instructions. The relative expression was quantified by the $\Delta\Delta C_T$ method by using GAPDH as the endogenous control and was performed using SDS software 2.2.0 (Applied Biosystems).

Immunohistochemical staining

In order to validate the quality of nasal epithelial cells by brushing the inferior turbinate with a Cytosoft Cytology Brush (Medical Packaging Co), nasal epithelial cells from 3 SAR-JCP and 3 control subjects were fixed on glass slides and stained for cytokeratin AE1/AE3 (Dako Corp., Carpinteria, CA) and vimentin (Dako).

Specimens of the inferior turbinate were collected from 6 patient with severe perennial nasal allergy and SAR symptoms (high levels of JC- and dust mite-specific serum IgE) and 5 Control subjects without nasal allergy. Characteristics of subjects for immunohistochemical staining is shown in Table S1. The inferior turbinate specimens were fixed in neutral buffered formalin (10%v/v formalin in water, pH 7.4) and embedded in paraffin wax. Immunohistochemical staining was performed on 4- μ m-thick sections using a CST1-specific antibody (Abnova Corporation, Taipei, Taiwan), as described previously [11].

Isolation of basophils and histamine release assay

Peripheral blood mononuclear cells (PBMCs) were isolated with Lymphoprep (Cosmo Bio, Tokyo, Japan) from heparinized whole blood drawn from 6 patients with SAR (3 males and 3 females, aged 24–36 years, high levels of JC-specific serum IgE). Basophils were separated from PBMCs by using a human basophil isolationkit (MiltenyiBiotec GmbH, BergischGladbach, Germany) according to the manufacturer's instructions. Basophils (2×10^4) were resuspended in RPMI1640 medium (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 100 U/mL penicillin (Sigma-Aldrich, St. Louis, MO), 100 μ g/mL streptomycin (Sigma-Aldrich), and 10% fetal calf serum (Thermo Fisher Scientific, Waltham, MA), and aliquoted at 200 μ L/well in 96-well microtiter plates. The plates were then incubated at 37°C in a humidified 5% CO₂ atmosphere for 30 min. The JC pollen allergen Cry j1 (10 μ g/mL; Torii, Tokyo, Japan) was preincubated with recombinant CST1 (200 ng/mL) for 30 min at 37°C, then aliquots of this mixture or Cry j1 alone were added to the

basophils and the plates were incubated for an additional 30 min. The concentration of histamine released into the supernatant was measured with a Histamine Enzyme Immunoassay kit (Bertin-Pharma, Montigny le Bretonneux, France) according to the manufacturer's instructions.

Statistical methods

Total and specific IgE levels were expressed as the geometric means with 95% confidence intervals (CI). Total and specific IgE data were log-transformed and statistical analyses of IgE levels and age were performed by Student's *t*-test or ANOVA. Statistical analysis of the gender ratio was evaluated with Fisher's exact test.

For the microarray analysis, background-corrected values for each probe on the BeadChip array were extracted using GenomeStudio software (Illumina). Detection *P*-values were computed from the background model characterized by the chance that the target sequence signal was distinguishable from the negative controls on the same chip. This is based on the average of negative control genes and is termed "the method of background normalization" by Illumina. We performed normexp-by-control background correction, quantile normalization, and log₂ transformation on the raw data using the "neqc" command of limma [12]. The normalized values were analyzed by using the R-2.13.1 statistical computing software (R-project, <http://www.r-project.org/>). Statistical significance of the microarray data was calculated using Welch's *t* test, and multiple tests were corrected by the Benjamini and Hochberg false discovery rate [13]. A heatmap of genes differentially expressed between SAR patients and Controls was generated using R-2.13.1 statistical computing software (R-project, <http://www.r-project.org/>). For comparison with the data generated in this study, we extracted the values for the gene expression in eosinophils from the data reported by Nakajima et al [14] (<http://www.nch.go.jp/imal/GeneChip/public.htm>). The qRT-PCR results were analyzed by Mann-Whitney's U test.

Gene Set Enrichment Analysis (GSEA) was performed using GSEA v2.0.9 [15] to explore the enriched gene sets related to SAR. We performed GSEA using a dataset provided by the GSEA website (c2.v2.symbols.gmt, <http://www.broadinstitute.org/gsea/downloads.jsp>), as well as with gene sets we manually curated. These sets comprised differentially expressed nasal epithelial genes from children with dust mite allergy (MITE_ALLERGY), genes




Figure 1. Heatmap of differentially expressed genes between SAR patients (SAR) and Controls (CON).
doi:10.1371/journal.pone.0067057.g001

differentially expressed (2-fold upregulated) during in vitro induction by IL-4 and IL-13 (IL-4_AND_IL-13), and those genes induced by IFNs (2-fold up) (IFN α , IFN β , and IFN γ) reported by Giovannini-Chami et al. [8]. The manually curated genes are listed in Table S2. The histamine release test results were analyzed using Wilcoxon signed-rank test.

Results

Highly expressed genes in nasal mucosa of subjects in the SAR-JC group

The immunohistochemical experiment revealed that most cells were positive for cytokeratin, suggesting most of the brushed nasal cells were of epithelial origin (Figure S1). To analyze differences in gene expression between the 7 SAR-JC subjects and 5 Control subjects in 2009, we first selected the transcripts that were expressed in at least 1 of the 12 samples and had detection P values of <0.01 on the BeadChip array. This yielded 13,188 expressed

transcripts. Transcripts were considered as upregulated or downregulated if they showed an average of greater than 2-fold increase or decrease in expression, and exhibited a statistically significant difference between the SAR and Control groups ($q < 0.05$). We identified 32 transcripts that were upregulated/downregulated in the nasal mucosa of the SAR subjects by at least 2-fold ($q < 0.05$) (Figure 1 and Table 2). Among them, several genes are known to be strongly expressed in eosinophils [14] (Charcot-Leyden crystal protein [*CLC*] and cadherin-like 26 [*CDH26*]), and GSEA analysis using the dataset of c2.v2.symbols.gmt revealed that the microarray dataset in the present study using 7 SAR patients and 5 Controls were enriched for the Top 30 increased eosinophil-specific transcripts (nominal $P = 0.006$ and FDR $q = 0.043$), suggesting that their upregulation in the SAR patients may partially be because of the infiltration of eosinophils into the nasal mucosa. GSEA using the gene dataset reported by Giovannini-Chami [8] revealed that genes upregulated in children with mite allergy (MITE ALLERGY) and genes induced by IL-4

Table 2. Genes significantly altered in nasal epithelial cells in SAR-JC patients.

Gene	Array address ID	NM numbers	Fold change	q values**
CST1*	6370541	NM_001898.2	64.6	0.031
ITLN1*	7610170	NM_017625.2	16.9	0.045
CLC	2030142	NM_001828.4	5.9	0.032
CDH26	4590541	NM_021810.3	5.2	0.031
NOS2A*	4760324	NM_153292.1	4.9	0.033
HDC	6280326	NM_002112.2	3.4	0.049
HIST1H2BD	290730	NM_138720.1	3.1	0.016
RPL14	2140753	NM_001034996.1	2.7	0.033
HIST1H2BD	6200669	NM_138720.1	2.5	0.033
OSTC	4610722	NM_021227.2	2.5	0.032
IL20RB*	3400095	NM_144717.2	2.4	0.031
ATP2C2	2510669	NM_014861.2	2.3	0.031
RRAS*	4570670	NM_006270.3	2.2	0.047
CFDP1	6200494	NM_006324.2	2.2	0.033
SDPR*	6290114	NM_004657.4	2.0	0.031
BCL2L15	1710575	NM_001010922.2	2.0	0.045
CAMK2G	1010475	NM_001222.2	-2.0	0.033
ZNF750	3420176	NM_024702.2	-2.1	0.032
SLC6A6	2810280	NM_003043.3	-2.2	0.031
NR1D2	2640707	XM_001130839.1	-2.2	0.031
MAP3K2	3800762	XM_001128799.1	-2.3	0.031
MAF	3610440	NM_005360.3	-2.3	0.033
SLC25A36	3870242	NM_018155.1	-2.3	0.041
GK5	6180543	NM_001039547.1	-2.4	0.041
SYT7*	5050390	NM_004200.2	-2.4	0.031
AKR1B1*	4260139	NM_001628.2	-2.4	0.025
ST3GALS*	5260403	NM_001042437.1	-2.4	0.031
OTX1*	1740438	NM_014562.2	-2.8	0.049
RORA	1110180	NM_002943.2	-2.9	0.044
PDE5A	1770333	NM_001083.3	-3.1	0.033
ANKRD36*	5810050	NM_198555.3	-4.1	0.044
ANKRD36B	3060010	NM_025190.2	-5.5	0.031

*Absent call in Eosinophils according to the data by Nakajima et al.

**Welch's t test, Benjamini-Hochberg FDR.

doi:10.1371/journal.pone.0067057.t002

and IL-13 (IL-4_AND_IL_13) were enriched in SAR patients in our dataset (Table 3). However, genes related to IFN responses were not enriched in our dataset.

We found that *CST1* (cystatin SN) was highly expressed in the SAR-JC subjects, undetectable in the Control subjects, and not expressed in eosinophils (absent call judged by the GeneChip Analysis Suite 5.0 program according to the data by Nakajima et al [14]; hence, we focused on *CST1* for further analysis. To validate the results of the microarray analysis, we measured *CST1* expression in the nasal mucosal samples from the 2009 subjects by qRT-PCR. As can be seen in Figure 2A, *CST1* expression was significantly higher in the SAR-JC group than in the Control group ($P=2.4 \times 10^{-7}$). To confirm these data, we also performed *CST1* qRT-PCR on nasal mucosal samples in 2010 (Figure 2B). Here, *CST1* expression was significantly higher in the SAR-JC

Table 3. GSEA using dataset of the study by Giovannini-Chami [5].

	Enrichment Score (ES)	Nominal ES (NES)	P value	q value
IL-4_AND_IL_13	0.73	1.85	0.004	0.027
MITE_ALLERGY	0.87	1.75	0.004	0.025
IFN α	0.21	0.74	0.78	0.89
IFN γ	0.19	0.66	0.83	0.75

doi:10.1371/journal.pone.0067057.t003

group than in the Sensitized group ($P=0.00087$) and Control group ($P=0.0006$), whereas there was no significant difference in expression between the Sensitized and Control groups ($P=0.13$).

We next investigated the expression of *CST1* protein by immunohistochemical staining of the inferior turbinate samples from 6 patients with perennial nasal allergy and SAR symptoms and 5 Control subjects without allergy. As shown in Figure 3, *CST1* was expressed in nasal epithelial cells in the SAR patients, but not in the Control subjects. To examine the effect of *CST1* on allergen-stimulated histamine release, basophils were isolated from the peripheral blood of 6 patients with SAR, and stimulated with the JC allergen Cry j 1 both in the presence and absence of *CST1*. Figure 4 shows that Cry j 1-stimulated histamine release by basophils was effectively inhibited in the presence of *CST1* ($P=0.032$).

Discussion

In the present study, we performed microarray analyses to identify SAR-related genes in nasal epithelial cells. We identified 36 genes that showed statistically significantly differed in SAR subjects compared with the Control group, and we confirmed by qRT-PCR that the expression of *CST1* was upregulated in SAR-JC patient compared with the Control group in both 2009 and 2010. We also showed that addition of exogenous *CST1* to basophils inhibited JC allergen-stimulated histamine release in vitro.

Cry j1 is a major antigen of Japanese cedar pollen [16]. It is a basic glycoprotein localized in the pollen cell wall, which has pectate lyase activity [17]. The epitope of Cry j1 is recognized by specific IgE of Cry j1 and released histamine from basophils by interacting antigen and antigen-specific IgE. Alteration of Cry j1 structure by heat denaturation leads to reduction of IgE-binding activities [18,19]. Therefore, histamine release from the basophils of patients induced by adding Cry j1 might be due to the degranulation via crosslinking of Cry j1-specific IgE already bound on the IgE receptor. Takai et al. reported that interaction of Der f 1, one of the major allergen of house dust mite with protease activity, and cystatin A, which belongs to cystatin superfamily, inhibited the binding of IgE in mite-allergic volunteers' sera, suggesting that cystatin A might change the binding site between antigen and antigen-specific IgE [20]. Thus, cystatin SN might affect the binding site between antigen and antigen-specific IgE, leading to the suppression of histamine release from basophils in the present study.

Cysteine proteases are widely expressed proteolytic enzymes that play roles in inflammatory tissue destruction as well as tissue remodeling [21]. The proteolytic activity of these enzymes is controlled by a family of inhibitors known as the cystatin superfamily [22], and cystatins inhibit cysteine proteases by forming tight but reversible complexes with their target enzymes.




Figure 2. Expression of *CST1* in nasal epithelial cells. RNA from nasal mucosa of Control subjects, Sensitized subjects, and patients with SAR-JC was analyzed for *CST1* expression by qRT-PCR. Expression of *CST1* in samples from (A) 2009 and (B) 2010. ns, not significant ($P > 0.05$); ***, $P < 0.001$. doi:10.1371/journal.pone.0067057.g002

Members of the type 2 cystatin subfamily are widely distributed [23], and include *CST1*, *CST2*, *CST3*, *CST4*, *CST5*, *CSTP1*, and *CSTP2*, which share >70% sequence similarity [24]. The *CST1* is expressed in the submandibular gland, gall bladder, and uterus [24]. *CST1* has been shown to bind tightly to the cysteine protease, papain, which is a potent allergen, and to inhibit the cysteine protease activity of papain [25].

Airborne allergens, such as those derived from pollen, cockroaches, fungi, and house dust mites, are proteases with the capacity to induce an inflammatory response. Previous studies have shown that the proteolytic activity of these allergens may facilitate sensitization, possibly by disrupting the balance between

protease and antiprotease activities. This theory is supported by the observation that the protease allergens reduce the antiprotease activity of the mucosa [26,27,28,29]. Der p 1 and Der f 1, the major allergens derived from house dust mites, are cysteine proteases that degrade α 1-antitrypsin inhibitor in the airway [28,29] and inactivate lung surfactant proteins A and D [26]. Cystatin A, a member of the cysteine protease inhibitor family, has been shown to suppress induction of Der f 1-specific IgE by modifying the interaction between Der f 1 and cystatin A, which may modulate the allergic inflammation and sensitization processes [20]. Thus, the cystatin family may play protective roles against allergens with protease activity.

Measurement of allergen-specific IgE in serum is widely used to diagnose allergic diseases such as SAR and asthma; however, subjects with allergen-specific IgE do not necessarily develop the allergic disease. Although many reports have described the pathophysiological features of allergic inflammation, biomarkers or genes that predict the onset of allergic rhinitis are yet to be reported. In this study, we observed that *CST1* was not expressed in cells from non-sensitized subjects, and that *CST1* expression was significantly lower in the IgE-positive Sensitized subjects than in the SAR-JC subjects. These data suggest that *CST1* may be a candidate marker gene to predict allergic rhinitis. We detected that 2 subjects in the Sensitized group showed particularly high *CST1* expression in the nasal mucosa, and we speculate that these subjects may have been close to developing SAR symptoms.

A recent study using nasal epithelial cells from children with dust mite allergy showed that *CST1* was the most highly upregulated gene and that *CST1* was also strongly induced by stimulation with IL-4 and IL-13 [8]. Therefore, *CST1* is likely to be upregulated in response to protease-containing allergens and the Th2 environment in the nasal mucosa. Because GSEA revealed that the genes upregulated in nasal brushing samples from mite allergic patients and the genes induced by IL-4 and IL-13 were significantly enriched in our dataset (Table 3), our data




Figure 3. Immunohistochemical staining of *CST1* in nasal epithelial cells. Representative immunostaining of *CST1* expression in the nasal epithelium of 2 SAR patients (A and B) and 2 Control subjects (C and D). Magnification: $\times 200$. doi:10.1371/journal.pone.0067057.g003




Figure 4. Histamine release by peripheral basophils stimulated with JC allergen. Cells were cultured with Cryj1 both in the presence and absence of recombinant CST1. *, $P < 0.05$. doi:10.1371/journal.pone.0067057.g004

support the notion that pathways underlying allergic rhinitis are common regardless of the allergen.

The balance between protease and antiprotease activities might thus be a key to distinguish between the sensitization stage and allergic response, and we suggest that cystatins contributes re-establishing homeostasis of the nasal mucosa.

Supporting Information

Figure S1 Immunohistochemical staining of cytokeratin and vimentin in brushed nasal epithelial cells. Representative immunostaining of cytokeratin expression (A and B) and vimentin expression (C and D). Magnification: $\times 200$. (PPTX)

References

- Nishima S, Chisaka H, Fujiwara T, Furusho K, Hayashi S, et al. (2009) Surveys on the prevalence of pediatric bronchial asthma in Japan: a comparison between the 1982, 1992, and 2002 surveys conducted in the same region using the same methodology. *Allergol Int* 58: 37–53.
- Okuda M (2003) Epidemiology of Japanese cedar pollinosis throughout Japan. *Ann Allergy Asthma Immunol* 91: 288–296.
- Sakashita M, Hirota T, Harada M, Nakamichi R, Tsunoda T, et al. (2010) Prevalence of allergic rhinitis and sensitization to common aeroallergens in a Japanese population. *Int Arch Allergy Immunol* 151: 255–261.
- McAleer MA, Irvine AD (2013) The multifunctional role of filaggrin in allergic skin disease. *J Allergy Clin Immunol* 131: 280–291.
- Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, et al. (2006) Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet* 38: 441–446.
- Chen JC, Chuang JG, Su YY, Chiang BL, Lin YS, et al. (2011) The protease allergen Pen c 13 induces allergic airway inflammation and changes in epithelial barrier integrity and function in a murine model. *J Biol Chem* 286: 26667–26679.

Table S1 Characteristics of subjects for immunohistochemical staining.

(XLSX)

Table S2 Manually curated gene sets used for GSEA.

(XLSX)

Acknowledgments

We are grateful to all participants in the study.

Author Contributions

Conceived and designed the experiments: Y. Imoto TA EN SF. Performed the experiments: Y. Imoto TT YM YH M. Ono TY Y. Ito. Analyzed the data: Y. Imoto TT EN. Contributed reagents/materials/analysis tools: Y. Imoto TY Y. Ito M. Okano SF. Wrote the paper: Y. Imoto TT TA EN SF.

7. Matsumoto Y, Noguchi E, Imoto Y, Nanatsue K, Takeshita K, et al. (2011) Upregulation of IL17RB during Natural Allergen Exposure in Patients with Seasonal Allergic Rhinitis. *Allergol Int* 60: 87–92.
8. Giovannini-Chami L, Marcet B, Moreilhon C, Chevalier B, Illie MI, et al. (2012) Distinct epithelial gene expression phenotypes in childhood respiratory allergy. *Eur Respir J* 39: 1197–1205.
9. Guajardo JR, Schleifer KW, Daines MO, Ruddy RM, Aronow BJ, et al. (2005) Altered gene expression profiles in nasal respiratory epithelium reflect stable versus acute childhood asthma. *J Allergy Clin Immunol* 115: 243–251.
10. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, et al. (2008) Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). *Allergy* 63 Suppl 86: 8–160.
11. Yoneda K, Iida H, Endo H, Hosono K, Akiyama T, et al. (2009) Identification of Cystatin SN as a novel tumor marker for colorectal cancer. *Int J Oncol* 35: 33–40.
12. Shi W, Oshlack A, Smyth GK (2010) Optimizing the noise versus bias trade-off for Illumina whole genome expression BeadChips. *Nucleic Acids Res* 38: e204.
13. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J R Stat Soc B* 57: 289–300.
14. Nakajima T, Iikura M, Okayama Y, Matsumoto K, Uchiyama C, et al. (2004) Identification of granulocyte subtype-selective receptors and ion channels by using a high-density oligonucleotide probe array. *J Allergy Clin Immunol* 113: 528–535.
15. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 102: 15545–15550.
16. Yasueda H, Yui Y, Shimizu T, Shida T (1983) Isolation and partial characterization of the major allergen from Japanese cedar (*Cryptomeria japonica*) pollen. *J Allergy Clin Immunol* 71: 77–86.
17. Taniguchi Y, Ono A, Sawatani M, Nanba M, Kohno K, et al. (1995) Cry j I, a major allergen of Japanese cedar pollen, has pectate lyase enzyme activity. *Allergy* 50: 90–93.
18. Hashimoto M, Nigi H, Sakaguchi M, Inouye S, Imaoka K, et al. (1995) Sensitivity to two major allergens (Cry j I and Cry j II) in patients with Japanese cedar (*Cryptomeria japonica*) pollinosis. *Clin Exp Allergy* 25: 848–852.
19. Sakaguchi M, Hashimoto M, Nigi H, Yasueda H, Takahashi Y, et al. (1997) Epitope specificity of IgE antibodies to a major allergen (Cry j I) of Japanese cedar pollen in sera of humans and monkeys with pollinosis. *Immunology* 91: 161–166.
20. Takai T, Kato T, Hatanaka H, Inui K, Nakazawa T, et al. (2009) Modulation of allergenicity of major house dust mite allergens Der f 1 and Der p 1 by interaction with an endogenous ligand. *J Immunol* 183: 7958–7965.
21. Koblinski JE, Ahram M, Sloane BF (2000) Unraveling the role of proteases in cancer. *Clin Chim Acta* 291: 113–135.
22. Barrett AJ (1986) The cystatins: a diverse superfamily of cysteine peptidase inhibitors. *Biomed Biochim Acta* 45: 1363–1374.
23. Henskens YM, Veerman EC, Nieuw Amerongen AV (1996) Cystatins in health and disease. *Biol Chem Hoppe Seyler* 377: 71–86.
24. Dickinson DP, Zhao Y, Thiess M, Siciliano MJ (1994) Direct mapping of seven genes encoding human type 2 cystatins to a single site located at 20p11.2. *Genomics* 24: 172–175.
25. Tseng CC, Tseng CP, Levine MJ, Bobek LA (2000) Differential effect toward inhibition of papain and cathepsin C by recombinant human salivary cystatin SN and its variants produced by a baculovirus system. *Arch Biochem Biophys* 380: 133–140.
26. Deb R, Shakib F, Reid K, Clark H (2007) Major house dust mite allergens *Dermatophagoides pteronyssinus* 1 and *Dermatophagoides farinae* 1 degrade and inactivate lung surfactant proteins A and D. *J Biol Chem* 282: 36808–36819.
27. Brown A, Farmer K, MacDonald L, Kalsheker N, Pritchard D, et al. (2003) House dust mite Der p 1 downregulates defenses of the lung by inactivating elastase inhibitors. *Am J Respir Cell Mol Biol* 29: 381–389.
28. Takai T, Kato T, Ota M, Yasueda H, Kuhara T, et al. (2005) Recombinant Der p 1 and Der f 1 with in vitro enzymatic activity to cleave human CD23, CD25 and alpha1-antitrypsin, and in vivo IgE-eliciting activity in mice. *Int Arch Allergy Immunol* 137: 194–200.
29. Kalsheker NA, Deam S, Chambers L, Sreedharan S, Brocklehurst K, et al. (1996) The house dust mite allergen Der p1 catalytically inactivates alpha 1-antitrypsin by specific reactive centre loop cleavage: a mechanism that promotes airway inflammation and asthma. *Biochem Biophys Res Commun* 221: 59–61.

